Sign In
Section Navigation
Common TitleACTG 302
Official Title Virologic Responses To New Nucleoside Regimens After Prolonged Zidovudine (ZDV) or Didanosine (ddI) Monotherapy
Phase Phase II
ClinicalTrials.gov NCT00000831
Treatments
Stavudine
Stavudine Zerit

Stavudine

Tradename:ZeritOther Names:d4TClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Categories Resistance/Virological FailureTreatment-ExperiencedMonotherapy
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
  • Katzenstein DA, Hughes MD, Albrecht M, et al. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 2001;17:203-10.
    [PubMed Abstract]
  • Shulman NS, Hughes MD, Winters MA, et al. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. J Acquir Immune Defic Syndr. 2002;31:121-7.
    [PubMed Abstract]
  • Shulman NS, Machekano RA, Shafer RW, et al. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr. 2001;27:377-80.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.